SLC16A3 and neoplasm: It has also been demonstrated that by regulating SLC16A3 in tumor cells, the TME's lactate levels can be reduced, leading to a decreased infiltration of inhibitory immune cells, and ultimately enhancing the sensitivity of tumor patients to immunotherapy [33].